Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.

Volpi C, Orabona C, Macchiarulo A, Bianchi R, Puccetti P, Grohmann U.

Expert Opin Drug Discov. 2019 Aug 7:1-14. doi: 10.1080/17460441.2019.1646244. [Epub ahead of print]

PMID:
31389262
2.

Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease.

Mondanelli G, Iacono A, Allegrucci M, Puccetti P, Grohmann U.

Front Immunol. 2019 Jul 9;10:1565. doi: 10.3389/fimmu.2019.01565. eCollection 2019. No abstract available.

3.

IL-35Ig-expressing dendritic cells induce tolerance via Arginase 1.

Panfili E, Mondanelli G, Orabona C, Bianchi R, Gargaro M, Fallarino F, Puccetti P, Grohmann U, Volpi C, Belladonna ML.

J Cell Mol Med. 2019 May;23(5):3757-3761. doi: 10.1111/jcmm.14215. Epub 2019 Feb 22.

4.

Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.

Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, Baglivo S, Chiari R, Pirro M.

Pharmacol Ther. 2019 Apr;196:105-116. doi: 10.1016/j.pharmthera.2018.12.004. Epub 2018 Dec 4. Review.

PMID:
30521884
5.

Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes.

Orabona C, Mondanelli G, Puccetti P, Grohmann U.

Trends Mol Med. 2018 Nov;24(11):931-941. doi: 10.1016/j.molmed.2018.08.005. Epub 2018 Sep 17. Review.

PMID:
30236470
6.

Reply to 'F508del-CFTR is not corrected by thymosin α1'.

Romani L, Stincardini C, Giovagnoli S, Paci M, Villella VR, Sforna L, Renga G, Bellet MM, Costantini C, Puccetti P, Kroemer G, Maiuri L, Pessia M, Goldstein A, Garaci E.

Nat Med. 2018 Jul;24(7):891-893. doi: 10.1038/s41591-018-0080-0. No abstract available.

PMID:
29942090
7.

Publisher Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis.

Romani L, Oikonomou V, Moretti S, Iannitti RG, D'Adamo MC, Villella VR, Pariano M, Sforna L, Borghi M, Bellet MM, Fallarino F, Pallotta MT, Servillo G, Ferrari E, Puccetti P, Kroemer G, Pessia M, Maiuri L, Goldstein AL, Garaci E.

Nat Med. 2018 Sep;24(9):1482. doi: 10.1038/s41591-018-0099-2.

PMID:
29934535
8.

Author Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis.

Romani L, Oikonomou V, Moretti S, Iannitti RG, D'Adamo MC, Villella VR, Pariano M, Sforna L, Borghi M, Bellet MM, Fallarino F, Pallotta MT, Servillo G, Ferrari E, Puccetti P, Kroemer G, Pessia M, Maiuri L, Goldstein AL, Garaci E.

Nat Med. 2018 Sep;24(9):1481. doi: 10.1038/s41591-018-0100-0.

PMID:
29934534
9.

S1P promotes migration, differentiation and immune regulatory activity in amniotic-fluid-derived stem cells.

Romani R, Manni G, Donati C, Pirisinu I, Bernacchioni C, Gargaro M, Pirro M, Calvitti M, Bagaglia F, Sahebkar A, Clerici G, Matino D, Pomili G, Di Renzo GC, Talesa VN, Puccetti P, Fallarino F.

Eur J Pharmacol. 2018 Aug 15;833:173-182. doi: 10.1016/j.ejphar.2018.06.005. Epub 2018 Jun 7.

10.

Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes.

Orabona C, Mondanelli G, Pallotta MT, Carvalho A, Albini E, Fallarino F, Vacca C, Volpi C, Belladonna ML, Berioli MG, Ceccarini G, Esposito SM, Scattoni R, Verrotti A, Ferretti A, De Giorgi G, Toni S, Cappa M, Matteoli MC, Bianchi R, Matino D, Iacono A, Puccetti M, Cunha C, Bicciato S, Antognelli C, Talesa VN, Chatenoud L, Fuchs D, Pilotte L, Van den Eynde B, Lemos MC, Romani L, Puccetti P, Grohmann U.

JCI Insight. 2018 Mar 22;3(6). pii: 96244. doi: 10.1172/jci.insight.96244.

11.

Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist.

Dolciami D, Gargaro M, Cerra B, Scalisi G, Bagnoli L, Servillo G, Fazia MAD, Puccetti P, Quintana FJ, Fallarino F, Macchiarulo A.

ChemMedChem. 2018 Feb 6;13(3):270-279. doi: 10.1002/cmdc.201700669. Epub 2018 Jan 23.

PMID:
29266750
12.

Disease Tolerance Mediated by Phosphorylated Indoleamine-2,3 Dioxygenase Confers Resistance to a Primary Fungal Pathogen.

de Araújo EF, Loures FV, Feriotti C, Costa T, Vacca C, Puccetti P, Romani L, Calich VLG.

Front Immunol. 2017 Nov 13;8:1522. doi: 10.3389/fimmu.2017.01522. eCollection 2017.

13.

Amino-acid sensing and degrading pathways in immune regulation.

Grohmann U, Mondanelli G, Belladonna ML, Orabona C, Pallotta MT, Iacono A, Puccetti P, Volpi C.

Cytokine Growth Factor Rev. 2017 Jun;35:37-45. doi: 10.1016/j.cytogfr.2017.05.004. Epub 2017 May 18. Review.

14.

Interaction of 7-Alkoxycoumarins with the Aryl Hydrocarbon Receptor.

Gargaro M, Epifano F, Fiorito S, Taddeo VA, Genovese S, Pirro M, Turco A, Puccetti P, Schmidt-Weber CB, Fallarino F.

J Nat Prod. 2017 Jun 23;80(6):1939-1943. doi: 10.1021/acs.jnatprod.7b00173. Epub 2017 May 19.

PMID:
28525281
15.

The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.

Mondanelli G, Albini E, Pallotta MT, Volpi C, Chatenoud L, Kuhn C, Fallarino F, Matino D, Belladonna ML, Bianchi R, Vacca C, Bicciato S, Boon L, Ricci G, Grohmann U, Puccetti P, Orabona C.

Front Immunol. 2017 Apr 13;8:428. doi: 10.3389/fimmu.2017.00428. eCollection 2017.

16.

Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis.

Romani L, Oikonomou V, Moretti S, Iannitti RG, D'Adamo MC, Villella VR, Pariano M, Sforna L, Borghi M, Bellet MM, Fallarino F, Pallotta MT, Servillo G, Ferrari E, Puccetti P, Kroemer G, Pessia M, Maiuri L, Goldstein AL, Garaci E.

Nat Med. 2017 May;23(5):590-600. doi: 10.1038/nm.4305. Epub 2017 Apr 10. Erratum in: Nat Med. 2018 Sep;24(9):1481. Nat Med. 2018 Sep;24(9):1482.

17.

CpG Type A Induction of an Early Protective Environment in Experimental Multiple Sclerosis.

Crooks J, Gargaro M, Vacca C, Volpi C, Pirro M, Scalisi G, Turco A, Romani R, Matino D, Rostami A, Puccetti P, Gran B, Fallarino F.

Mediators Inflamm. 2017;2017:1380615. doi: 10.1155/2017/1380615. Epub 2017 Mar 5.

18.

A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells.

Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, Belladonna ML, Vacca C, Fallarino F, Macchiarulo A, Ugel S, Bronte V, Gevi F, Zolla L, Verhaar A, Peppelenbosch M, Mazza EMC, Bicciato S, Laouar Y, Santambrogio L, Puccetti P, Volpi C, Grohmann U.

Immunity. 2017 Feb 21;46(2):233-244. doi: 10.1016/j.immuni.2017.01.005. Epub 2017 Feb 14.

19.

Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1.

Albini E, Rosini V, Gargaro M, Mondanelli G, Belladonna ML, Pallotta MT, Volpi C, Fallarino F, Macchiarulo A, Antognelli C, Bianchi R, Vacca C, Puccetti P, Grohmann U, Orabona C.

J Cell Mol Med. 2017 Jan;21(1):165-176. doi: 10.1111/jcmm.12954. Epub 2016 Sep 30.

20.

Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells.

Volpi C, Mondanelli G, Pallotta MT, Vacca C, Iacono A, Gargaro M, Albini E, Bianchi R, Belladonna ML, Celanire S, Mordant C, Heroux M, Royer-Urios I, Schneider M, Vitte PA, Cacquevel M, Galibert L, Poli SM, Solari A, Bicciato S, Calvitti M, Antognelli C, Puccetti P, Orabona C, Fallarino F, Grohmann U.

Neuropharmacology. 2016 Mar;102:59-71. doi: 10.1016/j.neuropharm.2015.10.036. Epub 2015 Oct 30.

21.

Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype.

Amantea D, Certo M, Petrelli F, Tassorelli C, Micieli G, Corasaniti MT, Puccetti P, Fallarino F, Bagetta G.

Exp Neurol. 2016 Jan;275 Pt 1:116-25. doi: 10.1016/j.expneurol.2015.10.012. Epub 2015 Oct 27.

PMID:
26518285
22.

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.

Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F.

J Clin Invest. 2015 Oct 1;125(10):3766-81. doi: 10.1172/JCI81859. Epub 2015 Aug 31.

23.

CD103(+) Dendritic Cells Control Th17 Cell Function in the Lung.

Zelante T, Wong AY, Ping TJ, Chen J, Sumatoh HR, Viganò E, Hong Bing Y, Lee B, Zolezzi F, Fric J, Newell EW, Mortellaro A, Poidinger M, Puccetti P, Ricciardi-Castagnoli P.

Cell Rep. 2015 Sep 22;12(11):1789-801. doi: 10.1016/j.celrep.2015.08.030. Epub 2015 Sep 10.

24.

Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers.

Puccetti P, Fallarino F, Italiano A, Soubeyran I, MacGrogan G, Debled M, Velasco V, Bodet D, Eimer S, Veldhoen M, Prendergast GC, Platten M, Bessede A, Guillemin GJ.

PLoS One. 2015 Apr 16;10(4):e0122046. doi: 10.1371/journal.pone.0122046. eCollection 2015.

25.

Comparative proteomic analysis of two distinct stem-cell populations from human amniotic fluid.

Romani R, Fallarino F, Pirisinu I, Calvitti M, Caselli A, Fiaschi T, Gamberi T, Matino D, Talesa VN, Donti E, Puccetti P, Modesti A, Magherini F.

Mol Biosyst. 2015 Jun;11(6):1622-32. doi: 10.1039/c5mb00018a. Epub 2015 Mar 26.

PMID:
25811139
26.

Stem cells from human amniotic fluid exert immunoregulatory function via secreted indoleamine 2,3-dioxygenase1.

Romani R, Pirisinu I, Calvitti M, Pallotta MT, Gargaro M, Bistoni G, Vacca C, Di Michele A, Orabona C, Rosati J, Pirro M, Giovagnoli S, Matino D, Prontera P, Rosi G, Grohmann U, Talesa VN, Donti E, Puccetti P, Fallarino F.

J Cell Mol Med. 2015 Jul;19(7):1593-605. doi: 10.1111/jcmm.12534. Epub 2015 Mar 17.

27.

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals.

Grohmann U, Puccetti P.

Front Immunol. 2015 Feb 12;6:58. doi: 10.3389/fimmu.2015.00058. eCollection 2015. No abstract available.

28.

AhR: far more than an environmental sensor.

Fallarino F, Romani L, Puccetti P.

Cell Cycle. 2014;13(17):2645-6. doi: 10.4161/15384101.2014.954219. No abstract available.

29.

The cross-talk between opportunistic fungi and the mammalian host via microbiota's metabolism.

Romani L, Zelante T, Palmieri M, Napolioni V, Picciolini M, Velardi A, Aversa F, Puccetti P.

Semin Immunopathol. 2015 Mar;37(2):163-71. doi: 10.1007/s00281-014-0464-2. Epub 2014 Nov 18. Review.

PMID:
25404119
30.

Ligand binding and functional selectivity of L-tryptophan metabolites at the mouse aryl hydrocarbon receptor (mAhR).

Nuti R, Gargaro M, Matino D, Dolciami D, Grohmann U, Puccetti P, Fallarino F, Macchiarulo A.

J Chem Inf Model. 2014 Dec 22;54(12):3373-83. doi: 10.1021/ci5005459. Epub 2014 Nov 21.

PMID:
25402742
31.

On the Non-Redundant Roles of TDO2 and IDO1.

Puccetti P.

Front Immunol. 2014 Oct 20;5:522. doi: 10.3389/fimmu.2014.00522. eCollection 2014. No abstract available.

32.

Romani & Puccetti reply.

Romani L, Puccetti P.

Nature. 2014 Oct 23;514(7523):E18. doi: 10.1038/nature13845. No abstract available.

PMID:
25341793
33.

LPS-conditioned dendritic cells confer endotoxin tolerance contingent on tryptophan catabolism.

Fallarino F, Pallotta MT, Matino D, Gargaro M, Orabona C, Vacca C, Mondanelli G, Allegrucci M, Boon L, Romani R, Talesa VN, Puccetti P, Grohmann U.

Immunobiology. 2015 Feb;220(2):315-21. doi: 10.1016/j.imbio.2014.09.017. Epub 2014 Sep 28.

PMID:
25278421
34.

Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi.

Romani L, Zelante T, De Luca A, Iannitti RG, Moretti S, Bartoli A, Aversa F, Puccetti P.

Eur J Immunol. 2014 Nov;44(11):3192-200. doi: 10.1002/eji.201344406. Epub 2014 Oct 20. Review.

35.

Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes.

Pallotta MT, Orabona C, Bianchi R, Vacca C, Fallarino F, Belladonna ML, Volpi C, Mondanelli G, Gargaro M, Allegrucci M, Talesa VN, Puccetti P, Grohmann U.

J Cell Mol Med. 2014 Oct;18(10):2082-91. doi: 10.1111/jcmm.12360. Epub 2014 Sep 12.

36.

[Metabolic therapy for heart failure].

Loiacono F, Alberti L, Lauretta L, Puccetti P, Silipigni C, Margonato A, Fragasso G.

Recenti Prog Med. 2014 Jul-Aug;105(7-8):288-94. doi: 10.1701/1574.17114. Review. Italian.

PMID:
25072544
37.

Aryl hydrocarbon receptor control of a disease tolerance defence pathway.

Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, Bianchi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Zelante T, Funakoshi H, Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P.

Nature. 2014 Jul 10;511(7508):184-90. doi: 10.1038/nature13323.

38.

NEDD4 controls the expression of GUCD1, a protein upregulated in proliferating liver cells.

Bellet MM, Piobbico D, Bartoli D, Castelli M, Pieroni S, Brunacci C, Chiacchiaretta M, Del Sordo R, Fallarino F, Sidoni A, Puccetti P, Romani L, Servillo G, Della Fazia MA.

Cell Cycle. 2014;13(12):1902-11. doi: 10.4161/cc.28760. Epub 2014 Apr 17.

39.

Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.

Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E.

J Clin Endocrinol Metab. 2014 May;99(5):E832-40. doi: 10.1210/jc.2013-3351. Epub 2014 Feb 11.

PMID:
24517146
40.

Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22.

Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D'Angelo C, Massi-Benedetti C, Fallarino F, Carvalho A, Puccetti P, Romani L.

Immunity. 2013 Aug 22;39(2):372-85. doi: 10.1016/j.immuni.2013.08.003.

41.

IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis.

De Luca A, Carvalho A, Cunha C, Iannitti RG, Pitzurra L, Giovannini G, Mencacci A, Bartolommei L, Moretti S, Massi-Benedetti C, Fuchs D, De Bernardis F, Puccetti P, Romani L.

PLoS Pathog. 2013;9(7):e1003486. doi: 10.1371/journal.ppat.1003486. Epub 2013 Jul 11.

42.

High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway.

Volpi C, Fallarino F, Pallotta MT, Bianchi R, Vacca C, Belladonna ML, Orabona C, De Luca A, Boon L, Romani L, Grohmann U, Puccetti P.

Nat Commun. 2013;4:1852. doi: 10.1038/ncomms2874.

PMID:
23673637
43.

Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines.

Iannitti RG, Carvalho A, Cunha C, De Luca A, Giovannini G, Casagrande A, Zelante T, Vacca C, Fallarino F, Puccetti P, Massi-Benedetti C, Defilippi G, Russo M, Porcaro L, Colombo C, Ratclif L, De Benedictis FM, Romani L.

Am J Respir Crit Care Med. 2013 Mar 15;187(6):609-20. doi: 10.1164/rccm.201207-1346OC. Epub 2013 Jan 10.

PMID:
23306541
44.

Indoleamine 2,3-dioxygenase: from catalyst to signaling function.

Fallarino F, Grohmann U, Puccetti P.

Eur J Immunol. 2012 Aug;42(8):1932-7. doi: 10.1002/eji.201242572. Review.

45.

A GpC-rich oligonucleotide acts on plasmacytoid dendritic cells to promote immune suppression.

Volpi C, Fallarino F, Bianchi R, Orabona C, De Luca A, Vacca C, Romani L, Gran B, Grohmann U, Puccetti P, Belladonna ML.

J Immunol. 2012 Sep 1;189(5):2283-9. doi: 10.4049/jimmunol.1200497. Epub 2012 Jul 27.

46.

Clotting factor concentrate switching and inhibitor development in hemophilia A.

Iorio A, Puccetti P, Makris M.

Blood. 2012 Jul 26;120(4):720-7. doi: 10.1182/blood-2012-03-378927. Epub 2012 Jun 12.

47.

Sensing of mammalian IL-17A regulates fungal adaptation and virulence.

Zelante T, Iannitti RG, De Luca A, Arroyo J, Blanco N, Servillo G, Sanglard D, Reichard U, Palmer GE, Latgè JP, Puccetti P, Romani L.

Nat Commun. 2012 Feb 21;3:683. doi: 10.1038/ncomms1685.

PMID:
22353714
48.

Improved survival in patients with chronic mild/moderate systolic heart failure followed up in a specialist clinic.

Fragasso G, Marinosci G, Calori G, Spoladore R, Arioli F, Bassanelli G, Salerno A, Cuko A, Puccetti P, Silipigni C, Palloshi A, Margonato A.

J Cardiovasc Med (Hagerstown). 2013 Jan;14(1):57-65. doi: 10.2459/JCM.0b013e32834ae697.

PMID:
22157180
49.

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells.

Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, Grohmann U.

Nat Immunol. 2011 Jul 31;12(9):870-8. doi: 10.1038/ni.2077.

PMID:
21804557
50.

Xenograft of microencapsulated sertoli cells reverses T1DM in NOD mice by inducing neogenesis of beta-cells.

Luca G, Fallarino F, Calvitti M, Mancuso F, Nastruzzi C, Arato I, Falabella G, Grohmann U, Becchetti E, Puccetti P, Calafiore R.

Transplantation. 2010 Dec 27;90(12):1352-7.

PMID:
21197711

Supplemental Content

Loading ...
Support Center